GeNeuro SA (GEM.F)
- Business Wire
GeNeuro Publishes its 2024 Universal Registration Document
GENEVA, Switzerland, May 02, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which has been filed on April 30, 2024 with the "Autorité des Marchés Financiers (AMF)".
- Business Wire
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update
GENEVA, April 30, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the year ended December 31, 2023, and provided a corporate update.
- Business Wire
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
GENEVA, March 20, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of March 18, 2024. These included among o
